DataSheet1_Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.PDF

Ferredoxin 1 (FDX1) functions by transferring electrons from NADPH to mitochondrial cytochrome P450 via the ferredoxin reductase and is the key regulator in copper-dependent cell death. Although mounting evidence supports a vital role for FDX1 in tumorigenesis of some cancers, no pan-cancer analysis of FDX1 has been reported. Therefore, we aimed to explore the prognostic value of FDX1 in pan-cancer and investigate its potential immune function. Based on data from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, Human Protein Atlas, and Gene Set Cancer Analysis, we used a range of bioinformatics approaches to explore the potential carcinogenic role of FDX1, including analyzing the relationship between FDX1 expression and prognosis, DNA methylation, RNA methylation-related genes, mismatch repair (MMR) gene, microsatellite instability (MSI), tumor mutation burden (TMB), tumor microenvironment (TME), immune-related genes, and drug sensitivity in different tumors. The results show that FDX1 was lowly expressed in most cancers but higher in glioblastoma multiforme, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. Moreover, FDX1 expression was positively or negatively associated with prognosis in different cancers. FDX1 expression was significantly associated with DNA methylation in 6 cancers, while there was a correlation between FDX1 expression and RNA methylation-related genes and MMR gene in most cancers. Furthermore, FDX1 expression was significantly associated with MSI in 8 cancers and TMB in 10 cancers. In addition, FDX1 expression was also significantly correlated with immune cell infiltration, immune-related genes, TME, and drug resistance in various cancers. An experiment in vitro showed FDX1 is downregulated by elesclomol, resulting in inhibiting cell viability of bladder cancer, clear cell renal cell carcinoma, and prostate cancer cells. Our study reveals that FDX1 can serve as a potential therapeutic target and prognostic marker for various malignancies due to its vital role in tumorigenesis and tumor immunity.</p

DataSheet2_Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.xlsx

Ferredoxin 1 (FDX1) functions by transferring electrons from NADPH to mitochondrial cytochrome P450 via the ferredoxin reductase and is the key regulator in copper-dependent cell death. Although mounting evidence supports a vital role for FDX1 in tumorigenesis of some cancers, no pan-cancer analysis of FDX1 has been reported. Therefore, we aimed to explore the prognostic value of FDX1 in pan-cancer and investigate its potential immune function. Based on data from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, Human Protein Atlas, and Gene Set Cancer Analysis, we used a range of bioinformatics approaches to explore the potential carcinogenic role of FDX1, including analyzing the relationship between FDX1 expression and prognosis, DNA methylation, RNA methylation-related genes, mismatch repair (MMR) gene, microsatellite instability (MSI), tumor mutation burden (TMB), tumor microenvironment (TME), immune-related genes, and drug sensitivity in different tumors. The results show that FDX1 was lowly expressed in most cancers but higher in glioblastoma multiforme, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. Moreover, FDX1 expression was positively or negatively associated with prognosis in different cancers. FDX1 expression was significantly associated with DNA methylation in 6 cancers, while there was a correlation between FDX1 expression and RNA methylation-related genes and MMR gene in most cancers. Furthermore, FDX1 expression was significantly associated with MSI in 8 cancers and TMB in 10 cancers. In addition, FDX1 expression was also significantly correlated with immune cell infiltration, immune-related genes, TME, and drug resistance in various cancers. An experiment in vitro showed FDX1 is downregulated by elesclomol, resulting in inhibiting cell viability of bladder cancer, clear cell renal cell carcinoma, and prostate cancer cells. Our study reveals that FDX1 can serve as a potential therapeutic target and prognostic marker for various malignancies due to its vital role in tumorigenesis and tumor immunity.</p

Body weight gain, total food intake and feeding efficiency of rats fed a high-cholesterol diet (control) or supplemented with different lactic acid bacteria strain (LA15, B23 and D17) diets after 4 weeks.

a<p>Mean values within a row with different superscripted letters differ significantly (<i>P</i><0.05).</p><p>The data are shown as the mean ± standard deviation, n = 10.</p>*<p>Food efficiency (%) = (body weight gain/food intake) ×100.</p

Adhesion ability of <i>Lactobacillus</i> isolates to Caco-2 epithelial cells compared with the reference strain <i>Lactobacillus rhamnosus</i> GG (LGG).

<p>The presented values are the means of triplicate determination, and the different letters (a, b) represent significant differences (<i>P</i><0.05).</p

Fecal cholic acid concentrations in rats fed a high-cholesterol diet alone (control) or supplemented with different lactic acid bacteria strains (LA15, B23 or D17) for 4 weeks.

<p>The results are expressed as the mean ± standard deviation. Mean values with different letters (a, b, c) differ significantly (<i>P</i><0.05).</p

Counts of different lactic acid bacteria strains (LA15, B23 or D17) in the duodemun, jejunum, ileum, colon and feces of rats.

a, b, c<p>Mean values within a column with different superscript letters were significantly different (<i>P</i><0.05).</p><p>The data are shown as the mean ± standard deviation.</p

Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels in the serum of rats fed a high-cholesterol diet alone (control) or supplemented with different lactic acid bacteria strains (LA15, B23 or D17) for 4 weeks.

<p>The results are expressed as the means ± standard deviation, n = 10. Means within the same lipid series with different lowercase letters (a-d) are significantly different (<i>P</i><0.05).</p

<i>In vitro</i> test of cholesterol-related activities of LAB isolated from Tibetan kefir grains.

a, b<p>Mean values within the same column with different superscripted letters differ significantly (<i>P</i><0.05).</p><p>The data are shown as the mean ± standard deviation.</p

Effects of probiotic feeding on fecal bacterial population.

a, b<p>Mean values within a column with different superscript letters were significantly different (<i>P</i><0.05).</p><p>The data are shown as the mean ± standard deviation.</p

Acid and bile tolerance of LAB strains (log CFU/ml).

a<p>Each value represents the mean value ± standard deviation (SD) from the 3 trials.</p>b<p>No growth.</p